方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 绒膜尿囊膜试验× | 溶血试验× | |
|---|---|---|
| 领域 | 生物材料 | 生物材料 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1974 | 1950 |
| 提出者≠ | Judah Folkman | Clinical hematology traditions |
| 类型≠ | Developmental biology assay | Hemolytic compatibility assay |
| 开创性文献≠ | Folkman, J. (1974). Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285(21), 1182-1186. link ↗ | ASTM F756-17 (2017). Standard Practice for Assessment of Hemolytic Properties of Materials. ASTM International. link ↗ |
| 别名 | chick embryo chorioallantoic membrane, angiogenesis assay, CAM angiogenesis model | RBC lysis assay, hemolytic compatibility test, hemolytic potential test |
| 相关 | 4 | 4 |
| 摘要≠ | The chorioallantoic membrane (CAM) assay is a well-established in vivo model for studying angiogenesis (new blood vessel formation) and evaluating the pro- or anti-angiogenic properties of biomaterials, drugs, and bioactive molecules. Developed by Judah Folkman in the 1970s, the assay uses the highly vascularized CAM of developing chick embryos as a platform for implanting test materials and observing vascular response. The CAM provides a transparent, immunologically naive microenvironment with rapid and reproducible neovascularization, making it ideal for screening angiogenic potential and assessing biomaterial biocompatibility. | The hemolysis assay is a standard method for evaluating the blood compatibility of biomaterials by quantifying the extent to which a material or substance damages red blood cells (RBCs) and causes hemoglobin release. Codified in standards including ASTM F756 and ISO 10993-4, the hemolysis assay is essential for regulatory approval of blood-contacting devices such as stents, catheters, artificial heart valves, and hemodialysis membranes. The assay provides a simple, quantitative measure of hemolytic potential that correlates with clinical safety. |
| ScholarGate数据集 ↗ |
|
|